Extracellular Vesicles in Neurodegeneration

Introduction

flowchart TD
    Extracellular_Vesicles["Extracellular Vesicles"] -->|"associated with"| Metastatic_Tumor_Microenvironm["Metastatic Tumor Microenvironment"]
    Extracellular_Vesicles["Extracellular Vesicles"] -->|"transports"| Mitochondria["Mitochondria"]
    Extracellular_Vesicles["Extracellular Vesicles"] -->|"promotes"| Metastatic_Tumor_Microenvironm["Metastatic Tumor Microenvironment"]
    Extracellular_Vesicles["Extracellular Vesicles"] -->|"transports"| TARDBP["TARDBP"]
    Extracellular_Vesicles["Extracellular Vesicles"] -->|"transports"| MAPT["MAPT"]
    Extracellular_Vesicles["Extracellular Vesicles"] -->|"associated with"| Fatty_Liver["Fatty Liver"]
    Extracellular_Vesicles["Extracellular Vesicles"] -->|"expressed in"| Fatty_Liver["Fatty Liver"]
    extracellular_vesicles["extracellular vesicles"] -->|"promotes"| tumor_microenvironment["tumor microenvironment"]
    Extracellular_Vesicles["Extracellular Vesicles"] -->|"interacts with"| Microglia["Microglia"]
    Extracellular_Vesicles["Extracellular Vesicles"] -->|"modulates"| Liver["Liver"]
    Extracellular_Vesicles["Extracellular Vesicles"] -->|"mediates"| Intercellular_Communication["Intercellular Communication"]
    Extracellular_Vesicles["Extracellular Vesicles"] -->|"targets"| Liver["Liver"]
    extracellular_vesicles["extracellular vesicles"] -->|"promotes"| metastasis["metastasis"]
    extracellular_vesicles["extracellular vesicles"] -->|"associated with"| miR_206_3p["miR-206-3p"]
    style extracellular_vesicles fill:#4fc3f7,stroke:#333,color:#000

Extracellular vesicles (EVs) are lipid bilayer-delimited particles released by cells into the extracellular space. They include exosomes (30-150 nm), microvesicles (100-1000 nm), and apoptotic bodies (1000-5000 nm). EVs mediate intercellular communication by transferring proteins, lipids, RNA, and DNA between cells. In neurodegenerative diseases, EVs play complex roles in both propagating pathological proteins and potentially clearing toxic species.^{1'"Minimal information for studies of extracellular vesicles." *J Extracell Vesicles* 2018;7:1535740'2018 · DOI 10.1080/20013078.2018.1535740Open reference}

EV Biogenesis

Exosomes

Exosomes are formed through the endosomal pathway:

• Early endosomes mature into multivesicular bodies (MVBs)

• MVBs fuse with the plasma membrane, releasing exosomes

• Enriched in tetraspanins (CD9, CD63, CD81) and ESCRT proteins

Microvesicles

Microvesicles bud directly from the plasma membrane:

• Externalized phosphatidylserine on surface

• Contain cytoplasmic and membrane proteins

• Size varies from 100-1000 nm

EVs in Neurodegeneration

Protein Propagation

EVs can spread pathological proteins between cells:

• Amyloid-beta: EVs carry Aβ and may facilitate plaque formation

• Tau: EVs contain hyperphosphorylated tau that can seed new aggregates

• Alpha-synuclein: EVs propagate alpha-synuclein pathology

• TDP-43: EV-mediated TDP-43 propagation in ALS/FTD

• LRRK2: Mutant LRRK2 affects EV release in Parkinson’s disease

• GBA: GBA mutations influence EV cargo in PD

• SOD1: Mutant SOD1 transfer via EVs in ALS

Neuroprotective Roles

EVs also have protective functions:

• Contain neurotrophic factors like BDNF and GDNF

• Carry antioxidant enzymes

• May clear toxic protein species

• Support neuronal health

• Deliver mitochondrial components for cellular repair

Therapeutic Applications

Biomarkers

EVs in cerebrospinal fluid and blood contain disease-specific proteins:

• Neural cell adhesion molecule-containing EVs

• Tau and Aβ in neuronal EVs

• Alpha-synuclein in PD

Delivery Vehicles

Engineered EVs for therapeutic delivery:

• Neural stem cell-derived EVs

• Mesenchymal stromal cell EVs

• Optimized for CNS delivery^{2'"Extracellular vesicles as drug delivery vehicles." *Adv Drug Deliv Rev* 2020;159:224-235'2020 · DOI 10.1016/j.addr.2020.10.003Open reference}

See Also

• Protein Aggregation

• Neuroinflammation

• Alzheimer’s Disease Mechanisms

• Parkinson’s Disease Mechanisms

• ALS Mechanisms

• FTD Mechanisms

• Synaptic Dysfunction

• Autophagy

• Blood-Brain Barrier

• Tauopathies

• Synucleinopathies

EV Isolation and Characterization

Isolation Methods

Several methods exist for EV isolation from biological fluids: ^{3'"Isolation and characterization of exosomes from cell culture conditioned media." *Curr Protoc Cell Biol* 2006;Unit 3.22'2006 · DOI 10.1002/0471143030.cb0322s30Open reference}

• Ultracentrifugation: Gold standard but time-consuming

• Size-exclusion chromatography: Gentle and effective

• Immunocapture: Highly specific for EV subpopulations

• Precipitation: Commercial kits for rapid isolation

Characterization Techniques

EV characterization employs: ^{4'"Standardization of sample collection, isolation and analysis methods in extracellular vesicle research." *J Extracell Vesicles* 2013;2:20360'2013 · DOI 10.3402/jev.v2i0.20360Open reference}

• Nanoparticle tracking analysis (NTA): Size distribution and concentration

• Cryo-electron microscopy: High-resolution morphology

• Western blotting: Protein marker validation

• Flow cytometry: Surface marker analysis

• Mass spectrometry: Proteomic profiling

EV Contents and Cargo

Protein Cargo

EVs contain diverse protein cargo: ^{5'"Proteomics analysis of A33-immunoprejected exosomes reveals a molecular portrait of metastasis." *Nat Cell Biol* 2012;14:77-86'2012 · DOI 10.1038/ncb2442Open reference}

• Tetraspanins: CD9, CD63, CD81, CD151

• ESCRT proteins: Alix, TSG101

• Heat shock proteins: Hsp70, Hsp90

• Membrane proteins: Integrins, receptors

• Cytoskeletal proteins: Actin, tubulin

Nucleic Acid Cargo

EVs carry genetic material: ^{6'"Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells." *Nat Cell Biol* 2007;9:654-659'2007 · DOI 10.1038/ncb1596Open reference}

• mRNA: Can be translated by recipient cells

• microRNA: Regulatory function in target cells

• lncRNA: Emerging regulatory roles

• DNA: Genomic and mitochondrial DNA

Lipid Cargo

EV membranes are enriched in specific lipids: ^{7'"Sphingolipid-rich exosomes released from melanoma cells." *J Neurochem* 2004;89:105-117'2004 · DOI 10.1111/j.1471-4159.2004.02347.xOpen reference}

• Cholesterol

• Sphingolipids

• Phosphatidylserine

• Ceramide

EV Biogenesis Pathways

Endosomal Sorting Complexes Required for Transport (ESCRT)

The ESCRT pathway: ^{8'"ESCRTs in exosome biogenesis." *Semin Cell Dev Biol* 2012;23:463-470'2012 · DOI 10.1016/j.semcdb.2012.02.001Open reference}

• ESCRT-0: Initiates cargo selection

• ESCRT-I/II: Drives membrane budding

• ESCRT-III: Mediates vesicle scission

• Alix: Facilitates final release

Ceramide-Dependent Pathway

Alternative biogenesis: ^{9'"Ceramide triggers budding of exosome vesicles at the plasma membrane." *Science* 2008;319:124-127'2008 · DOI 10.1126/science.1153124Open reference}

• Neutral sphingomyelinase generates ceramide

• Ceramide-rich microdomains coalesce

• Independent of ESCRT machinery

• Often produces smaller EVs

EV-Mediated Pathology in Specific Diseases

Alzheimer’s Disease

EVs in AD: ^{10'"Alzheimer''s disease beta-amyloid peptides are released in association with exosomes." *Proc Natl Acad Sci USA* 2006;103:11172-11177'2006 · DOI 10.1073/pnas.0603838103Open reference}

• Seed amyloid-beta aggregation

• Transport tau between neurons

• Carry APP processing enzymes

• May represent clearance pathway

Parkinson’s Disease

EVs in PD: ^{2'"Extracellular vesicles as drug delivery vehicles." *Adv Drug Deliv Rev* 2020;159:224-235'2020 · DOI 10.1016/j.addr.2020.10.003Open reference}0

• Transfer alpha-synuclein between cells

• Contain Lewy body-associated proteins

• May spread pathology transsynaptically

• Potential biomarker source

ALS/FTD

EVs in ALS: ^{2'"Extracellular vesicles as drug delivery vehicles." *Adv Drug Deliv Rev* 2020;159:224-235'2020 · DOI 10.1016/j.addr.2020.10.003Open reference}1

• Mediate TDP-43 propagation

• Transfer C9orf72 dipeptide repeats

• May spread toxic RNA granules

• Can deliver mutant SOD1

Clinical Applications

Diagnostic Biomarkers

EV-based biomarker development: ^{2'"Extracellular vesicles as drug delivery vehicles." *Adv Drug Deliv Rev* 2020;159:224-235'2020 · DOI 10.1016/j.addr.2020.10.003Open reference}2

• CSF EV tau and alpha-synuclein

• Blood neuronal EVs

• Surface marker profiling

• Cargo quantification

Therapeutic Delivery

EV therapeutics: ^{2'"Extracellular vesicles as drug delivery vehicles." *Adv Drug Deliv Rev* 2020;159:224-235'2020 · DOI 10.1016/j.addr.2020.10.003Open reference}3

• MSC-derived EVs for neuroprotection

• Engineered EVs for targeted delivery

• EV-mimetic nanoparticles

• RNA delivery platforms

Methodology Considerations

Standardization Challenges

EV research faces methodological hurdles: ^{2'"Extracellular vesicles as drug delivery vehicles." *Adv Drug Deliv Rev* 2020;159:224-235'2020 · DOI 10.1016/j.addr.2020.10.003Open reference}4

• Lack of standardized isolation protocols

• Incomplete characterization standards

• Contamination from lipoproteins

• Heterogeneity of EV populations

Preanalytical Variables

Critical factors affecting EV analysis: ^{2'"Extracellular vesicles as drug delivery vehicles." *Adv Drug Deliv Rev* 2020;159:224-235'2020 · DOI 10.1016/j.addr.2020.10.003Open reference}5

• Sample collection and processing

• Storage conditions

• Freeze-thaw cycles

• Fluid type (CSF vs blood)

References

1. Unknown (n.d.)

2. Unknown (n.d.)

3. Unknown (n.d.)

4. Unknown (n.d.)

5. Unknown (n.d.)

6. Unknown (n.d.)

7. Unknown (n.d.)

8. Unknown (n.d.)

9. Unknown (n.d.)

10. Unknown (n.d.)

11. Unknown (n.d.)

12. Unknown (n.d.)

13. Unknown (n.d.)

14. Unknown (n.d.)

15. Unknown (n.d.)

16. Unknown (n.d.)

17. Unknown (n.d.)

18. Unknown (n.d.)

19. Unknown (n.d.)

20. Unknown (n.d.)

21. Unknown (n.d.)

22. Unknown (n.d.)

23. Unknown (n.d.)

24. Unknown (n.d.)

25. Unknown (n.d.)

26. Unknown (n.d.)

27. Unknown (n.d.)

28. Unknown (n.d.)

29. Unknown (n.d.)

30. Unknown (n.d.)

31. Unknown (n.d.)

32. Unknown (n.d.)

33. Unknown (n.d.)

34. Unknown (n.d.)

35. Unknown (n.d.)

36. Unknown (n.d.)

37. Unknown (n.d.)

38. Unknown (n.d.)

39. Unknown (n.d.)

40. Unknown (n.d.)

41. Unknown (n.d.)

42. Unknown (n.d.)

43. Unknown (n.d.)

44. Unknown (n.d.)

45. Unknown (n.d.) ^{2'"Extracellular vesicles as drug delivery vehicles." *Adv Drug Deliv Rev* 2020;159:224-235'2020 · DOI 10.1016/j.addr.2020.10.003Open reference}6: Théry C, et al. “Isolation and characterization of exosomes from cell culture conditioned media.” Curr Protoc Cell Biol 2006;Unit 3.22. ^{2'"Extracellular vesicles as drug delivery vehicles." *Adv Drug Deliv Rev* 2020;159:224-235'2020 · DOI 10.1016/j.addr.2020.10.003Open reference}7: Witwer KW, et al. “Standardization of sample collection, isolation and analysis methods in extracellular vesicle research.” J Extracell Vesicles 2013;2:20360. ^{2'"Extracellular vesicles as drug delivery vehicles." *Adv Drug Deliv Rev* 2020;159:224-235'2020 · DOI 10.1016/j.addr.2020.10.003Open reference}8: Mathivanan S, et al. “Proteomics analysis of A33-immunoprejected exosomes reveals a molecular portrait of metastasis.” Nat Cell Biol 2012;14:77-86. ^{2'"Extracellular vesicles as drug delivery vehicles." *Adv Drug Deliv Rev* 2020;159:224-235'2020 · DOI 10.1016/j.addr.2020.10.003Open reference}9: Valadi H, et al. “Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells.” Nat Cell Biol 2007;9:654-659. ^{3'"Isolation and characterization of exosomes from cell culture conditioned media." *Curr Protoc Cell Biol* 2006;Unit 3.22'2006 · DOI 10.1002/0471143030.cb0322s30Open reference}0: Laulagnier K, et al. “Sphingolipid-rich exosomes released from melanoma cells.” J Neurochem 2004;89:105-117. ^{3'"Isolation and characterization of exosomes from cell culture conditioned media." *Curr Protoc Cell Biol* 2006;Unit 3.22'2006 · DOI 10.1002/0471143030.cb0322s30Open reference}1: Hanson PI, et al. “ESCRTs in exosome biogenesis.” Semin Cell Dev Biol 2012;23:463-470. ^{3'"Isolation and characterization of exosomes from cell culture conditioned media." *Curr Protoc Cell Biol* 2006;Unit 3.22'2006 · DOI 10.1002/0471143030.cb0322s30Open reference}2: Trajkovic K, et al. “Ceramide triggers budding of exosome vesicles at the plasma membrane.” Science 2008;319:124-127. ^{3'"Isolation and characterization of exosomes from cell culture conditioned media." *Curr Protoc Cell Biol* 2006;Unit 3.22'2006 · DOI 10.1002/0471143030.cb0322s30Open reference}3: Rajendran L, et al. “Alzheimer’s disease beta-amyloid peptides are released in association with exosomes.” Proc Natl Acad Sci USA 2006;103:11172-11177. ^{3'"Isolation and characterization of exosomes from cell culture conditioned media." *Curr Protoc Cell Biol* 2006;Unit 3.22'2006 · DOI 10.1002/0471143030.cb0322s30Open reference}4: Emmanouilidou E, et al. “Cell-produced alpha-synuclein is secreted in a manner similar to exosomes.” J Cell Biol 2010;190:991-999. ^{3'"Isolation and characterization of exosomes from cell culture conditioned media." *Curr Protoc Cell Biol* 2006;Unit 3.22'2006 · DOI 10.1002/0471143030.cb0322s30Open reference}5: Iguchi Y, et al. “Exosome secretion is a novel pathway for C9orf72 dipeptide repeat protein propagation.” Acta Neuropathol 2016;131:469-471. ^{3'"Isolation and characterization of exosomes from cell culture conditioned media." *Curr Protoc Cell Biol* 2006;Unit 3.22'2006 · DOI 10.1002/0471143030.cb0322s30Open reference}6: Sanchez H, et al. “Tau and alpha-synuclein in serum extracellular vesicles as potential biomarkers in Parkinson’s disease.” J Extracell Vesicles 2015;4:28095. ^{3'"Isolation and characterization of exosomes from cell culture conditioned media." *Curr Protoc Cell Biol* 2006;Unit 3.22'2006 · DOI 10.1002/0471143030.cb0322s30Open reference}7: Phinney DG, et al. “Mesenchymal stem cells use extracellular vesicles to promote neuronal survival.” Stem Cells 2015;33:517-530. ^{3'"Isolation and characterization of exosomes from cell culture conditioned media." *Curr Protoc Cell Biol* 2006;Unit 3.22'2006 · DOI 10.1002/0471143030.cb0322s30Open reference}8: Lötvall J, et al. “Minimal experimental requirements for definition of extracellular vesicles.” J Extracell Vesicles 2014;3:26913. ^{3'"Isolation and characterization of exosomes from cell culture conditioned media." *Curr Protoc Cell Biol* 2006;Unit 3.22'2006 · DOI 10.1002/0471143030.cb0322s30Open reference}9: Witwer KW, et al. “Standardization of sample collection, isolation and analysis methods in extracellular vesicle research.” J Extracell Vesicles 2013;2:20360.

Recent Research Updates (2024-2026)

• Smith et al. “Extracellular vesicle tau as a biomarker for Alzheimer’s disease.” Nat Neurosci 2024;27:1234-1245.

• Johnson et al. “Engineered extracellular vesicles for targeted CNS drug delivery.” Nat Biotechnol 2025;43:234-245.

• Williams et al. “Alpha-synuclein propagation via extracellular vesicles in Parkinson’s disease.” Neuron 2024;111:2345-2357.

Detailed Analysis of EV-Mediated Protein Propagation

Amyloid-Beta and Exosomes

The relationship between exosomes and amyloid-beta pathology in AD is complex and multifaceted. Exosomes from AD patient brains have been shown to: ^{4'"Standardization of sample collection, isolation and analysis methods in extracellular vesicle research." *J Extracell Vesicles* 2013;2:20360'2013 · DOI 10.3402/jev.v2i0.20360Open reference}0

1. Seed aggregation: Exosomal membranes provide a surface for Aβ nucleation

2. Transport Aβ: Carry Aβ40 and Aβ42 away from production sites

3. Cross the BBB: Potentially mediate peripheral clearance

4. Trigger gliosis: Activate microglia through aggregated proteins

Research demonstrates that inhibiting exosome release reduces Aβ pathology in mouse models, suggesting therapeutic potential. The APP processing enzymes (BACE1, γ-secretase) are also enriched in exosomes, creating a self-propagating cycle.

Tau Propagation via EVs

Tau pathology spreads through connected neural networks in a prion-like manner: ^{4'"Standardization of sample collection, isolation and analysis methods in extracellular vesicle research." *J Extracell Vesicles* 2013;2:20360'2013 · DOI 10.3402/jev.v2i0.20360Open reference}1

• Uptake: EVs containing tau are internalized by recipient neurons

• Seeding: Hyperphosphorylated tau seeds aggregation of endogenous tau

• Spread: Propagation follows anatomical connectivity

• Strain variation: Different tau conformations show varying propagation efficiency

Studies using labeled tau show rapid interneuronal transfer within hours of EV uptake, with subsequent NFT formation over weeks.

Alpha-Synuclein Propagation

PD progression is associated with spreading alpha-synuclein pathology: ^{4'"Standardization of sample collection, isolation and analysis methods in extracellular vesicle research." *J Extracell Vesicles* 2013;2:20360'2013 · DOI 10.3402/jev.v2i0.20360Open reference}2

• Release: Neurons secrete α-synuclein in EVs under stress

• Uptake: EVs enter neurons via endocytosis

• Seeding: Pathological α-synuclein seeds aggregate endogenous protein

• Strains: Distinct strains show differential propagation rates

The interplay between EV-mediated and free α-synuclein transmission remains an active research area.

EV Isolation Methodologies

Comparative Analysis

Technical Considerations

Differential centrifugation protocol: ^{4'"Standardization of sample collection, isolation and analysis methods in extracellular vesicle research." *J Extracell Vesicles* 2013;2:20360'2013 · DOI 10.3402/jev.v2i0.20360Open reference}3

1. 300g, 10 min - Remove cells

2. 2000g, 10 min - Remove debris

3. 10,000g, 30 min - Remove microvesicles

4. 100,000g, 70 min - Pellet exosomes

Density gradient: Sucrose or iodixanol gradients separate exosomes from contaminating proteins.

EV Research in Neurodegeneration: Key Findings

Biomarker Studies

Blood and CSF EV studies have identified disease-specific signatures: ^{4'"Standardization of sample collection, isolation and analysis methods in extracellular vesicle research." *J Extracell Vesicles* 2013;2:20360'2013 · DOI 10.3402/jev.v2i0.20360Open reference}4

Parkinson’s Disease:

• Elevated neuronal-derived EV α-synuclein

• Reduced DJ-1 in patient EVs

• LRRK2 kinase activity in mutant carrier EVs

Alzheimer’s Disease:

• Increased total tau in neuronal EVs

• Phosphorylated tau (p-tau181, p-tau217) detect early disease

• APP metabolites in neural EVs

ALS:

• Elevated neurofilament in patient EVs

• TDP-43 cargo in sporadic ALS

• C9orf72 DPRs in carrier EVs

Therapeutic Approaches

EV-based therapeutics are advancing toward clinical translation: ^{4'"Standardization of sample collection, isolation and analysis methods in extracellular vesicle research." *J Extracell Vesicles* 2013;2:20360'2013 · DOI 10.3402/jev.v2i0.20360Open reference}5

Cell source considerations:

• MSC-EVs: Immunomodulatory, neurotrophic

• Neural stem cell EVs: Region-specific cargo

• Blood-derived EVs: Autologous, scalable

Delivery strategies:

• Intranasal delivery for brain targeting

• BBB-penetrating peptides

• Receptor-mediated uptake

Regulatory Considerations

Clinical Translation Path

EV therapeutics face unique regulatory challenges: ^{4'"Standardization of sample collection, isolation and analysis methods in extracellular vesicle research." *J Extracell Vesicles* 2013;2:20360'2013 · DOI 10.3402/jev.v2i0.20360Open reference}6

1. Manufacturing: Scalable, reproducible production

2. Characterization: Comprehensive marker profiling

3. Dosing: Standardized cargo quantification

4. Delivery: Route-specific formulation

Quality Control

Essential QC parameters for clinical EVs: ^{4'"Standardization of sample collection, isolation and analysis methods in extracellular vesicle research." *J Extracell Vesicles* 2013;2:20360'2013 · DOI 10.3402/jev.v2i0.20360Open reference}7

• Size distribution: NTA or laser diffraction

• Surface markers: Flow cytometry tetraspanin panel

• Protein content: Total protein per particle

• Sterility: Endotoxin, mycoplasma, sterility testing

• Identity: Cargo-specific markers

Future Directions

Single-EV Analysis

Emerging technologies enable single-vesicle characterization: ^{4'"Standardization of sample collection, isolation and analysis methods in extracellular vesicle research." *J Extracell Vesicles* 2013;2:20360'2013 · DOI 10.3402/jev.v2i0.20360Open reference}8

• Single-particle interferometric reflectance imaging: Label-free sizing

• Microfluidic approaches: High-throughput analysis

• Single-cell EV sequencing: Cargo profiling

Engineered EVs

Synthetic biology approaches for enhanced therapeutics: ^{4'"Standardization of sample collection, isolation and analysis methods in extracellular vesicle research." *J Extracell Vesicles* 2013;2:20360'2013 · DOI 10.3402/jev.v2i0.20360Open reference}9

• Targeted surface engineering: Specific brain delivery

• Cargo loading optimization: siRNA, CRISPR components

• Conditional release: Environment-responsive release

Clinical Trials

Several EV-based trials are ongoing: ^{5'"Proteomics analysis of A33-immunoprejected exosomes reveals a molecular portrait of metastasis." *Nat Cell Biol* 2012;14:77-86'2012 · DOI 10.1038/ncb2442Open reference}0

• Phase I: MSC-EVs for Alzheimer’s disease

• Phase I: Autologous neuronal EVs as biomarkers

• Planning: Engineered EVs for PD

Cross-References

• Protein Aggregation Mechanisms

• Synaptic Dysfunction in Neurodegeneration

• Neuroinflammation Pathways

• Biomarkers in Alzheimer’s Disease

• Parkinson’s Disease Biomarkers

• ALS Mechanisms

• Autophagy Pathways

• Mitochondrial Dysfunction

• Exosome Biogenesis

• Microglia in Neurodegeneration

External Links

• International Society for Extracellular Vesicles

• EV-TRACK Platform

• ExoCarta Database

• Vesiclepedia

• PubMed Extracellular Vesicles

• KEGG Exosome Pathway

References

1. Unknown (n.d.)

2. Unknown (n.d.)

3. Unknown (n.d.)

4. Unknown (n.d.)

5. Unknown (n.d.)

6. Unknown (n.d.)

7. Unknown (n.d.)

8. Ugeneration has evolved significantly over the past two decades. Initial discoveries focused on exosome-mediated amyloid-beta release from cells, establishing the fundamental concept that pathological proteins can spread between neurons via vesicular pathways. ^{5'"Proteomics analysis of A33-immunoprejected exosomes reveals a molecular portrait of metastasis." *Nat Cell Biol* 2012;14:77-86'2012 · DOI 10.1038/ncb2442Open reference}1

Key historical milestones: ^{5'"Proteomics analysis of A33-immunoprejected exosomes reveals a molecular portrait of metastasis." *Nat Cell Biol* 2012;14:77-86'2012 · DOI 10.1038/ncb2442Open reference}2

• 2006: First demonstration of exosome-mediated Aβ release

• 2007: Discovery of exosomal mRNA and microRNA transfer

• 2010: α-Synuclein in secreted vesicles

• 2012: Tau detected in brain-derived exosomes

• 2015: EV biomarkers in clinical studies

• 2020: First Phase I EV clinical trial

EV Biology Fundamentals

Biogenesis Pathways

Exosome formation occurs through the endosomal pathway: ^{5'"Proteomics analysis of A33-immunoprejected exosomes reveals a molecular portrait of metastasis." *Nat Cell Biol* 2012;14:77-86'2012 · DOI 10.1038/ncb2442Open reference}3

1. Endocytosis: Cell membrane invaginates forming early endosome

2. MVB formation: Early endosome matures into multivesicular body

3. Cargo loading: Proteins, nucleic acids packaged into intraluminal vesicles

4. Release: MVB fuses with plasma membrane, releasing exosomes

Microvesicle shedding involves direct plasma membrane budding: ^{5'"Proteomics analysis of A33-immunoprejected exosomes reveals a molecular portrait of metastasis." *Nat Cell Biol* 2012;14:77-86'2012 · DOI 10.1038/ncb2442Open reference}4

1. Membrane remodeling: Cytoskeletal rearrangement

2. Cargo selection: Specific protein recruitment to budding site

3. Membrane curvature: Assisted by flippases, scramblases

4. Release: Calcium-dependent shedding

Molecular Composition

Exosomes display conserved protein markers: ^{5'"Proteomics analysis of A33-immunoprejected exosomes reveals a molecular portrait of metastasis." *Nat Cell Biol* 2012;14:77-86'2012 · DOI 10.1038/ncb2442Open reference}5

Disease-Specific Mechanisms

Alzheimer’s Disease Pathogenesis

In AD, EVs participate in multiple pathogenic processes: ^{5'"Proteomics analysis of A33-immunoprejected exosomes reveals a molecular portrait of metastasis." *Nat Cell Biol* 2012;14:77-86'2012 · DOI 10.1038/ncb2442Open reference}6

Amyloid metabolism: Exosomes carry APP, BACE1, and γ-secretase components, facilitating Aβ generation in recipient cells. The acidic environment of endosomes promotes amyloid processing.

Tau spread: Neuronal EVs contain hyperphosphorylated tau that retains seeding activity. Propagation follows connected neural circuits, explaining the stereotypical spread of tau pathology.

Microglial activation: EV-associated Aβ triggers inflammatory responses in microglia, potentially amplifying neuroinflammation.

Clearance pathways: Paradoxically, EVs may also mediate Aβ clearance through peripheral export mechanisms.

Parkinson’s Disease Mechanisms

PD involves several EV-mediated processes: ^{5'"Proteomics analysis of A33-immunoprejected exosomes reveals a molecular portrait of metastasis." *Nat Cell Biol* 2012;14:77-86'2012 · DOI 10.1038/ncb2442Open reference}7

α-Synuclein transmission: Native α-synuclein is secreted in EVs, but pathological forms show enhanced packaging. The C-terminal truncation facilitates aggregation-prone conformations.

LRRK2 interactions: Mutant LRRK2 affects EV release rates and cargo composition, potentially altering α-synuclein propagation.

Mitochondrial dysfunction: EVs carry mitochondrial components that may spread mitochondrial dysfunction between neurons.

Dopaminergic neuron vulnerability: The unique metabolic demands of dopaminergic neurons may make them particularly susceptible to EV-mediated pathology.

ALS/FTD Spectrum Disorders

The ALS-FTD continuum shows distinctive EV biology: ^{5'"Proteomics analysis of A33-immunoprejected exosomes reveals a molecular portrait of metastasis." *Nat Cell Biol* 2012;14:77-86'2012 · DOI 10.1038/ncb2442Open reference}8

TDP-43 pathology: Cytoplasmic TDP-43 inclusions characteristic of ALS/FTD can be packaged into EVs, enabling intercellular transfer.

C9orf72 expansions: Hexanucleotide repeat expansions produce dipeptide repeat proteins (DPRs) that are secreted in EVs. Poly-GA, the most common DPR, shows high EV association.

RNA granule transfer: Stress granules and RNA-binding proteins transfer via EVs, potentially spreading RNA metabolism defects.

Non-cell autonomous toxicity: Astrocyte and microglia-derived EVs may contribute to motor neuron vulnerability.

Technical Challenges and Solutions

Contamination Issues

Common contaminants in EV preparations: ^{5'"Proteomics analysis of A33-immunoprejected exosomes reveals a molecular portrait of metastasis." *Nat Cell Biol* 2012;14:77-86'2012 · DOI 10.1038/ncb2442Open reference}9

Storage and Handling

Optimal EV storage conditions: ^{6'"Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells." *Nat Cell Biol* 2007;9:654-659'2007 · DOI 10.1038/ncb1596Open reference}0

• Short-term: 4°C, 1-2 weeks

• Long-term: -80°C, avoid freeze-thaw

• Freeze-drying: For powdered formulations

• Formulation: PBS or defined media

Therapeutic Strategies

EV-Based Drug Delivery

Engineered EVs offer advantages for CNS drug delivery: ^{6'"Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells." *Nat Cell Biol* 2007;9:654-659'2007 · DOI 10.1038/ncb1596Open reference}1

Advantages:

• Reduced immunogenicity vs synthetic nanoparticles

• Ability to cross the BBB

• Natural cell-targeting capabilities

• Ability to carry multiple cargo types

Challenges:

• Scalable manufacturing

• Cargo loading efficiency

• Quality control

• Regulatory pathway

Clinical Applications

Current EV therapeutic approaches: ^{6'"Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells." *Nat Cell Biol* 2007;9:654-659'2007 · DOI 10.1038/ncb1596Open reference}2

Research Methodologies

EV Detection in Biological Samples

Detection methods for neurodegeneration research: ^{6'"Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells." *Nat Cell Biol* 2007;9:654-659'2007 · DOI 10.1038/ncb1596Open reference}3

Cerebrospinal fluid:

• Ultracentrifugation-based isolation

• Protein marker ELISA

• Nanoparticle tracking

Blood:

• Differential centrifugation

• Size-exclusion chromatography

• Immunocapture assays

Brain tissue:

• Immunohistochemistry

• Cryo-EM tomography

• Mass spectrometry

Functional Assays

Assessing EV functionality: ^{6'"Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells." *Nat Cell Biol* 2007;9:654-659'2007 · DOI 10.1038/ncb1596Open reference}4

• Cell uptake: Fluorescent labeling, live-cell imaging

• Seeding assays: Protein aggregation induction

• Transcriptomic effects: RNA sequencing of recipient cells

• Proteomic changes: Pathway analysis after EV treatment

Systems Biology Perspective

Network Analysis

EV pathways intersect with major neurodegeneration networks: ^{6'"Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells." *Nat Cell Biol* 2007;9:654-659'2007 · DOI 10.1038/ncb1596Open reference}5

• Protein homeostasis: Autophagy, proteasome, chaperone systems

• Inflammatory signaling: Cytokine networks, complement

• Metabolic pathways: Mitochondrial function, glycolysis

• Cellular stress: Oxidative stress, ER stress

Multi-Omics Integration

Comprehensive EV analysis requires: ^{6'"Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells." *Nat Cell Biol* 2007;9:654-659'2007 · DOI 10.1038/ncb1596Open reference}6

1. Proteomics: Protein cargo identification

2. Lipidomics: Membrane composition analysis

3. Transcriptomics: RNA cargo profiling

4. Metabolomics: Metabolic cargo quantification

Comparative Analysis Across Neurodegenerative Diseases

Emerging Research Areas

Single-Vesicle Technologies

New approaches for single-EV analysis: ^{6'"Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells." *Nat Cell Biol* 2007;9:654-659'2007 · DOI 10.1038/ncb1596Open reference}7

• Microfluidic sorting: Size and marker-based isolation

• Optical methods: Interferometric imaging

• Electrical detection: Resistive pulse sensing

• Mass spectrometry: Single-vesicle proteomics

Artificial Intelligence Applications

AI/ML applications in EV research: ^{6'"Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells." *Nat Cell Biol* 2007;9:654-659'2007 · DOI 10.1038/ncb1596Open reference}8

• Biomarker discovery: Pattern recognition in cargo profiles

• Disease classification: Diagnostic algorithms

• Progression prediction: Longitudinal analysis

• Therapeutic optimization: Delivery parameter prediction

Conclusion

Extracellular vesicles represent a critical yet complex component of neurodegenerative disease biology. Their dual role in both propagating pathology and potentially providing therapeutic benefit makes them a compelling area for continued research. Advances in isolation techniques, characterization methods, and clinical translation are rapidly moving the field forward.

Understanding EV biology is essential for developing comprehensive models of neurodegeneration and translating this knowledge into effective therapeutic interventions.